Merus

MA BD deal handshake cooperation collaboration business deal
Pharma

2025's top biopharma M&A deals

Looming patent expirations and a thawing of the biotech investment scene prompted drug developers of all stripes to pull out their checkbooks in 2025.
Go sign green light

Merus' Bizengri wins FDA nod as 1st drug to target NRG1+ cancers

Dec 4, 2024 6:55pm
ESMO 2023 Sunday

Rain in Spain doesn't dampen spirits of 33,000 oncologists

Oct 23, 2023 8:58am